SCRI-CAR19x22v2 / Seattle Children's Hospital - LARVOL DELTA

PLAT-05: A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia (clinicaltrials.gov) - P1 | N=78 | Active, not recruiting | Sponsor: Seattle Children's Hospital | Recruiting ➔ Active, not recruiting

CAR T-Cell Therapy • Enrollment closed • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Pediatrics • CD22

PLAT-05: A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Seattle Children's Hospital | Trial primary completion date: Jun 2023 ➔ Sep 2023

CAR T-Cell Therapy • Trial primary completion date • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Pediatrics • CD22

PLAT-05: A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Seattle Children's Hospital | Trial primary completion date: Dec 2022 ➔ Jun 2023

CAR T-Cell Therapy • Trial primary completion date • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Pediatrics • CD19 • CD22

Dual CAR T-Cell for ALL (SOHO 2022) - P1, P1/2 | "Quantitative PCR data demonstrated that CART22-65s and huCART19 had different peak expansions that correlated with distinct cytokine release syndrome events...Early results have demonstrated manufacturing feasibility and anti-leukemia activity; however, limited dual functionality has been observed in some products. Longer follow-up and additional studies are needed to ascertain remission durability and to further optimize dual-targeted CARs."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD22

SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL (ASH 2021) - P1 | "We demonstrate enhanced activity of SCRI-CAR19x22v2 compared to v1, now with dual activity against both CD19 and CD22 demonstrated by elimination of ALL with single antigen expression. We maintained encouraging CR rates with a favorable toxicity profile. Interestingly, the product is predominated by CD22 CAR and CD19/CD22 CAR populations, while in vivo engraftment is predominated by single CD22 CAR expressing T cells."

Hematological Malignancies • Immune Modulation • Inflammation • Leukemia • Oncology • CD19 • CD22 • CD4 • CD8

PLAT-05: A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Seattle Children's Hospital | N=60 ➔ 80 | Trial completion date: Nov 2034 ➔ Mar 2035 | Trial primary completion date: Mar 2022 ➔ Dec 2022

CAR T-Cell Therapy • Enrollment change • Trial completion date • Trial primary completion date • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Pediatrics • CD19 • CD22